These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 18387689)

  • 1. Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer.
    Kaltenthaler E; Tappenden P; Booth A; Akehurst R
    Health Policy; 2008 Sep; 87(3):389-400. PubMed ID: 18387689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
    Chilcott J; Lloyd Jones M; Wilkinson A
    Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of paclitaxel in the management of early stage breast cancer.
    Griffin S; Dunn G; Palmer S; Macfarlane K; Brent S; Dyker A; Erhorn S; Humphries C; White S; Horsley W; Ferrie L; Thomas S
    Health Technol Assess; 2009 Jun; 13 Suppl 1():15-22. PubMed ID: 19567209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
    Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
    J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
    Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
    Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
    Webber-Foster R; Kvizhinadze G; Rivalland G; Blakely T
    Pharmacoeconomics; 2014 Jul; 32(7):707-24. PubMed ID: 24859241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
    Dranitsaris G; Coleman R; Gradishar W
    Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib for the treatment of multiple myeloma patients.
    Green C; Bryant J; Takeda A; Cooper K; Clegg A; Smith A; Stephens M
    Health Technol Assess; 2009 Jun; 13 Suppl 1():29-33. PubMed ID: 19567211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxanes in the treatment of early breast cancer.
    Ring AE; Ellis PA
    Cancer Treat Rev; 2005 Dec; 31(8):618-27. PubMed ID: 16266787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
    Dang CT
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):427-36. PubMed ID: 16503859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
    Walker S; Palmer S; Erhorn S; Brent S; Dyker A; Ferrie L; Horsley W; Macfarlane K; White S; Thomas S
    Health Technol Assess; 2009 Jun; 13 Suppl 1():35-40. PubMed ID: 19567212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
    Ravdin PM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
    Bria E; Nistico C; Cuppone F; Carlini P; Ciccarese M; Milella M; Natoli G; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2006 Jun; 106(11):2337-44. PubMed ID: 16649217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer.
    Limwattananon S; Limwattananon C; Maoleekulpairoj S; Soparatanapaisal N
    J Med Assoc Thai; 2006 May; 89(5):690-8. PubMed ID: 16756057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib for the treatment of HER2-overexpressing breast cancer.
    Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab for the treatment of adults with psoriasis.
    Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
    Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.